MCCQE1 practice questions: Diabetes Canada diagnosis, screening and A1C targets

Three full clinical vignettes with worked explanations. The thresholds are the easy part. What questions actually test is whether one abnormal result is enough to diagnose, and whether you can resist tightening an A1C in a patient for whom 7.0% is the wrong target.

Written by MCCQE1 Tutor editorial team, AYRIQ Technologies · Updated 16 November 2026

These are free samples. The full platform builds papers from the Canadian guidelines, grades them, and tracks every topic you get wrong.

Diagnosis, screening, target

Diagnostic thresholds

Fasting plasma glucose≥ 7.0 mmol/L
A1C≥ 6.5%
2-hour plasma glucose in a 75 g OGTT≥ 11.1 mmol/L
Random plasma glucose≥ 11.1 mmol/L

In a person without symptoms, one abnormal result does not make the diagnosis. A confirmatory laboratory test is required, and if it is a repeat of the same test it is done on another day. A random plasma glucose in the diabetic range is confirmed with a different test. Where symptoms of hyperglycaemia are present, a single result in the diabetic range is enough, and the guideline is explicit that treatment need not wait for a confirmatory test.

Screening

Screen with fasting plasma glucose and/or A1C every 3 years from age 40, or at any age in someone at high risk on a risk calculator — which the guideline quantifies as a 33% chance of developing diabetes over 10 years. Someone at very high risk, or with additional risk factors, is tested earlier and followed up every 6 to 12 months. CANRISK is the usual calculator in Canada, and it has not been validated below the age of 40.

The A1C target is not one number

Most adults with diabetes≤ 7.0%
Some adults with type 2 diabetes, to further lower kidney and eye risk ≤ 6.5% — but only in someone assessed to be at low risk of hypoglycaemia, judged on the class of drug they take and on their own characteristics. The guideline writes this recommendation for type 2 diabetes; it does not extend it to type 1.
Functionally dependent7.1–8.0%
Frail, or living with dementia7.1–8.5%
Limited life expectancy, or recurrent severe hypoglycaemia / hypoglycaemia unawareness 7.1–8.5%
End of lifeMeasuring A1C is not recommended. Avoid symptomatic hyperglycaemia and avoid any hypoglycaemia.

One refinement worth carrying, because it changes the number: for older adults the guideline splits these bands by how much hypoglycaemia the treatment risks. The 7.1–8.0% and 7.1–8.5% bands are written for people whose therapy includes insulin or a sulfonylurea. Where the regimen carries little hypoglycaemia risk, the same groups are given targets of simply below 8.0% and below 8.5% — no lower bound, because there is little to protect them from.

Three practice questions

Question 1 · One abnormal result

A 46-year-old man attends for a periodic health examination. He is entirely asymptomatic, with no polyuria, polydipsia or weight loss. His BMI is 31 kg/m². Screening blood work returns an A1C of 6.8%. He feels well and his examination is unremarkable. Which of the following is the most appropriate next step?

Show the answer and explanation

Correct answer: B. Arrange a confirmatory test before making the diagnosis

His A1C of 6.8% is at or above the diagnostic threshold of 6.5%. But he has no symptoms of hyperglycaemia, and in an asymptomatic person a single abnormal result is not a diagnosis. A confirmatory test is required: a repeat A1C, or a fasting plasma glucose that is also in the diabetic range.

The reason is practical. A1C is affected by haemoglobinopathies, iron deficiency, recent transfusion, pregnancy, and conditions that alter red cell turnover; assays vary; and a diagnosis of diabetes is permanent, affecting insurance, licensing and employment as well as treatment. Confirming costs one blood test.

The exception worth holding alongside this: a patient with classic symptomatic hyperglycaemia and an unequivocally raised glucose is diagnosed on that, without waiting to repeat anything.

Why the other options are wrong

  • A. Right threshold, premature action. Starting metformin commits him to a diagnosis and a drug on the strength of a single unconfirmed result.
  • C. An A1C of 6.8% is above the diabetes threshold, not in the prediabetes range, and a three-year wait would leave genuine diabetes untreated.
  • D. A1C is a recognised diagnostic test in Canada. An OGTT is a reasonable confirmatory option in some situations but is not required because A1C is somehow invalid.
  • E. This confuses a treatment target with a diagnostic threshold. The 7.0% figure is where you aim once someone has diabetes; 6.5% is where the diagnosis begins.
Guideline anchor: Diabetes Canada: diabetes may be diagnosed in an asymptomatic individual by A1C ≥6.5% on two tests, fasting plasma glucose ≥7.0 mmol/L on two tests, or A1C ≥6.5% together with fasting plasma glucose ≥7.0 mmol/L.
Question 2 · Who to screen, and how often

A 41-year-old woman with no symptoms attends for a routine visit. Her BMI is 24 kg/m², her blood pressure is normal, she has no family history of diabetes, no history of gestational diabetes, and belongs to no higher-risk population group. She asks whether she should be tested for diabetes. Which of the following is most consistent with Diabetes Canada guidance?

Show the answer and explanation

Correct answer: B. Screen now with fasting plasma glucose and/or A1C, and repeat every 3 years

Screening is recommended every three years from the age of 40, using fasting plasma glucose and/or A1C. Age alone puts her in the screening population; she does not need an additional risk factor to qualify.

A risk calculator such as CANRISK identifies people who should be screened earlier or more frequently — it does not excuse someone over 40 from screening because their score is low. The two criteria run in parallel: age 40, or high risk at any age.

Her thin build is a distractor with real teaching value. Type 2 diabetes in a lean patient is less common but not rare, and a normal BMI is not a reason to skip age-based screening.

Why the other options are wrong

  • A. This treats risk factors as the only route into screening. Age 40 is a criterion in its own right.
  • C. Annual screening is more than the guidance recommends for someone at average risk, and tests people three times as often for no established gain.
  • D. Fifty is the colorectal screening age in most provinces, not the diabetes screening age. Mixing up the two programmes is a common slip.
  • E. An OGTT is more burdensome and is not the recommended first-line screening test here. Fasting plasma glucose and A1C are.
Guideline anchor: Diabetes Canada, screening for diabetes in adults: screen with fasting plasma glucose and/or A1C every 3 years in individuals aged 40 or over, or in those at high risk identified using a risk calculator.
Question 3 · When 7.0% is the wrong target

An 84-year-old woman with type 2 diabetes lives in long-term care. She has moderate dementia, is dependent for most activities of daily living, and has fallen twice in the past six months. She takes gliclazide and metformin. Nursing staff report two episodes in the past month of confusion and sweating that resolved with juice; a capillary glucose during one episode was 3.1 mmol/L. Her A1C today is 7.2%. Which of the following is the most appropriate management?

Show the answer and explanation

Correct answer: B. Reduce or stop the gliclazide and accept a higher A1C target

Her A1C of 7.2% looks reassuring and is in fact a warning. For a frail older adult living with dementia, the recommended target is 7.1–8.5%, and a history of recurrent hypoglycaemia points to the same range. The lower bound of that band applies to her precisely because her therapy includes a sulfonylurea; on a regimen with little hypoglycaemia risk the guideline would simply say "below 8.5%". She is sitting at the very bottom of her appropriate target while having documented hypoglycaemic episodes. She is, in other words, overtreated.

The drug to address is the gliclazide. Sulfonylureas cause hypoglycaemia; metformin on its own essentially does not. Reducing or stopping it is the intervention that fits the problem.

The stakes here are not abstract. Hypoglycaemia in an older adult with dementia presents as confusion, which is easily attributed to the dementia itself, and it causes falls — she has had two. In this population a hip fracture is a far more immediate threat than the microvascular complications a tighter A1C would be aiming at over decades she does not have.

Why the other options are wrong

  • A. This is the reflex the question is testing. Intensifying therapy in a frail patient already experiencing hypoglycaemia increases harm in pursuit of a target that does not apply to her.
  • C. Her A1C is near a target that is not hers, and "unchanged" leaves the sulfonylurea causing the episodes in place.
  • D. Insulin carries more hypoglycaemia risk, not less, and metformin is not the agent causing the problem.
  • E. Adding an agent lowers glucose further in someone who is already going too low.
Guideline anchor: Diabetes Canada, targets for glycaemic control and diabetes in older people: ≤7.0% for most adults; 7.1–8.0% where functionally dependent; 7.1–8.5% where frail or living with dementia, where life expectancy is limited, or with recurrent severe hypoglycaemia or hypoglycaemia unawareness.

Four traps this topic sets

1. 6.5% versus 7.0%. 6.5% is where the diagnosis starts. 7.0% is where treatment usually aims. Swapping them produces a confident wrong answer in either direction.

2. Diagnosing on one test. In an asymptomatic person, confirm. The exception is symptomatic hyperglycaemia with an unequivocally raised glucose.

3. Treating the target as universal. A frail 84-year-old and a healthy 45-year-old do not share a target, and a stem that spends three lines on frailty, falls and dementia is telling you which one applies.

4. Reading a good A1C as good control. In an older adult on a sulfonylurea, a low A1C with hypoglycaemic episodes is overtreatment wearing the costume of success.

Sources

Every figure on this page is traceable to one of these. Guidelines are revised — open the source before you commit a number to memory.

  1. Diabetes Canada, chapter 3 — Definition, Classification and Diagnosis — the diagnostic thresholds and the confirmatory-test rule
  2. Diabetes Canada, chapter 4 — Screening for Diabetes in Adults — the screening interval, the age criterion, and the risk-calculator route
  3. Diabetes Canada, chapter 8 — Targets for Glycemic Control — the A1C target bands and when to individualise them
  4. Diabetes Canada, chapter 37 — Diabetes in Older People — the frailty target table, the hypoglycaemia-risk split, and long-term care
  5. Diabetes Canada — Clinical Practice Guidelines quick reference guide (PDF) — the thresholds and targets on two pages

More free MCCQE1 practice questions

See all free MCCQE1 practice topics →

About these practice pages

MCCQE1 Tutor is a Canadian-guideline preparation platform for the Medical Council of Canada Qualifying Examination Part 1, built by AYRIQ Technologies. The questions on this page were written for this page and are given away free. They are not drawn from the subscriber question bank, so working through them uses up nothing you have paid for.

Practising on Canadian numbers is the whole point. Everything here is free; the platform is where it becomes a study plan.